LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

ERBA Mannheim Opens New Subsidiary in Brazil

By LabMedica International staff writers
Posted on 12 Sep 2019
ERBA Mannheim has expanded its global footprint by opening a new subsidiary in Brazil. The new organization, Erba Mannheim Brazil, will be headquartered in Nova Lima, north of the nation’s capital, will sell a full range of blood and urine test automation solutions in clinical chemistry, hematology, hemostasis, immunoassay, urinalysis, diabetes, critical care and microbiology.

“This new operation significantly enhances our footprint in LATAM,” said Nikhil Vazirani, MD of Erba Mannheim. “We have an excellent team who are looking forward to helping improve workflow and quality whilst reducing cost and turnaround time of Brazilian labs.”

“We are very excited to be able to serve our customers and support our channel partners from within Brazil,” said Tarcisio Vilhena, Brazil country manager. “We have a dedicated team ready to support our customers with application and service expertise as well as sales and marketing support. From the simplest semi-automatic system to the impressive sophistication of our future NEXUS range, we are committed to help improve the lives of millions in Brazil through high quality, affordable automation.”

Erba Mannheim Brazil also showcased key products, including XL200 and XL640 clinical chemistry instruments, LAURA XL automatic urinalysis system, Elite 580 and H560 automatic hematology analyzers and the ECL760 automatic coagulation analyzer, at the 53rd Brazilian Congress of Clinical Pathology in Rio Janeiro, held September 24-27, 2019.

ERBA Mannheim

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Rapid Molecular Testing Device
FlashDetect Flash10

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more